undefined undefined undefined

Cardiovascular drug adherence and persistence: relevance and implementation

Event: ESC Congress 2025

Topic: Cardiovascular Pharmacotherapy

Session type: Symposium

Access

Like

Challenges in antiarrhythmic pharmacotherapy

Event: EuroCVP 2023 – The annual meeting on advances in cardiovascular pharmacotherapy

Topic: Cardiovascular Pharmacotherapy

Session type: Teaching Course

Access

Like

Cardiovascular Pharmacotherapy in Women

Event: EuroCVP 2023 – The annual meeting on advances in cardiovascular pharmacotherapy

Topic: Cardiovascular Pharmacotherapy

Session type: Teaching Course

Access

Like

The new era of SGLT2 Inhibitors in Cardiovascular Disease: beyond glucose control

Event: EuroCVP 2023 – The annual meeting on advances in cardiovascular pharmacotherapy

Topic: Cardiovascular Pharmacotherapy

Session type: Teaching Course

Access

Like

Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

Event: ESC Congress 2023

Topic: Anticoagulants

Session type: Moderated ePosters

Access

Like

Oral anticoagulation in patients with atrial fibrillation

Event: ESC Congress 2023

Topic: Anticoagulants

Session type: Moderated ePosters

Access

Like

Strategies to improve cardiovascular pharmacotherapy in older people

Event: Pharmacotherapy in Older People (POP) 2023

Topic: Pharmacology and Pharmacotherapy

Session type: Symposium

Access

Like

Welcome address

Event: Pharmacotherapy in Older People (POP) 2023

Topic: Working Groups

Session type: Special Event

Access

Like

Heart failure with reduced ejection fraction (HFrEF) 1

Event: Heart Failure 2023

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session type: Moderated ePosters

Access

Like

Heart failure with reduced ejection fraction (HFrEF) 3

Event: Heart Failure 2023

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session type: Moderated ePosters

Access

Like

undefined undefined undefined

Contributor content

Cardiovascular drug adherence and persistence: relevance and implementation

Challenges in antiarrhythmic pharmacotherapy

Cardiovascular Pharmacotherapy in Women

The new era of SGLT2 Inhibitors in Cardiovascular Disease: beyond glucose control

Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

Oral anticoagulation in patients with atrial fibrillation

Strategies to improve cardiovascular pharmacotherapy in older people

Welcome address

Heart failure with reduced ejection fraction (HFrEF) 1

Heart failure with reduced ejection fraction (HFrEF) 3

ESC 365 is supported by